STOCKHOLM, Sweden, Nov. 30, 2005 (PRIMEZONE) -- Members of Meda's new executive management team bought a total of 1,625,000 warrants in Meda. This team was formed after the Viatris acquisition. Each warrant entitles the right to subscribe for one new share in the company at SEK 150 per share -- as per the extraordinary general meeting decision in October 2005. The subscription period runs from 27 February 2006 to 26 February 2008. Going forward, additional key persons in the new Group will get opportunities to participate in the warrants programme.
The executive management team consists of Anders Lonner (Chief Executive Officer), Jorg-Thomas Dierks (Chief Operating Officer), Anders Larnholt (Vice President Business Development & Investor Relations), Wilhelm Plumpe (Vice President Group Services), Henrik Stenqvist (Chief Financial officer), and Marten Osterlund (Vice President of Scientific Affairs).
MEDA AB (publ) -- the Swedish specialty pharmaceutical company. Meda markets prescription and over-the-counter drugs and medical equipment. The company is listed on the Stockholm stock exchange's (Stockholmsborsen) Attract 40 list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=157732&fn=wkr0010.pdf